Hourly refreshWed, Oct 28, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Healthcare

3,047 press releases in English indexed under healthcare.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
DownloadExcelTXT
Healthcare

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

-- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozan

Oct 25 · 08:35Business Wire
Healthcare · Marketing & advertising

Bronwen Sciortino Wins 'Author of the Year' at Influencer Magazine Awards 2026

LONDON, UNITED KINGDOM, October 25, 2026 / EINPresswire.com / -- Bronwen Sciortino , internationally recognised author, speaker and thought leader on health, wellbeing and sustainable success, has been awarded Author of the Year at the Influencer Magazine Awards (E3) on October 25, 2026, honouring her writing and thought leadership that challenges the belief that success must come at the expense of our health, happin

Oct 25 · 07:45EIN Presswire
Finance · Healthcare

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy.

Oct 25 · 07:30GlobeNewswire
SaaS · Healthcare

Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026

FMC-376 is an equipotent ON+OFF KRAS G12C inhibitor designed with the Frontier™ Platform to address limitations of current KRAS G12C inhibitors, including resistance and tolerability Treatment with FMC-376 in the Phase 1A portion of the trial led to confirmed overall objective response rate of 56% in NSCLC patients, inclu

Oct 25 · 07:30Business Wire
Healthcare · Education

Lubbock Plastic Surgeon Dr. Thanapoom Boonipat Leads Suturing Workshop for Texas Tech Women in STEM Premed Students

Suturing workshop

Oct 25 · 07:0024-7 Press Release
Finance · Healthcare

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"

Oct 25 · 06:15PressReach
Healthcare · Biotech & pharma

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors"

Oct 25 · 06:15PressReach
Healthcare · Energy

Easy Fitness Routines You Can Do at Home

Exercise helps you build your strength, boost your mood and increase your energy levels. But many people may feel put off by the cost, especially if they have a lot of other financial obligations weighing on them. Fitness doesn't have to be expensive, however. There are many ways to work out at home that can make a significant difference in your health. Just as a debt consolidation loan helps make it easier to tackle

Oct 25 · 04:00Newswire.com
Healthcare · Biotech & pharma

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC)....

Oct 25 · 01:00PR Newswire
Healthcare · Retail

Dr. Agravat Dental Clinic Implant Wellness Center Integrates 10-Minute Blinkit Delivery

This clinical-to-quick-commerce bridge eliminates traditional 3- to 7-day e-commerce shipping delays, allowing patient

Oct 25 · 00:56freePRnow
Finance · SaaS

HotelKey Announces Strategic Leadership Updates to Expand Global Footprint and Drive Operational Excellence

CARROLLTON, TX, Oct 25, 2026 - HotelKey, the leading cloud-based property management platform for the hospitality industry, today announced strategic updates to its leadership bench. Driving the company's vision and global scaling efforts are Julie Arrowsmith, Executive Vice President and Chief Financial Officer (EVP & CFO); Craig Chait, Vice President, Asia-Pacific (VP, APAC); Adnan Malik, Vice President, Europe, Middle East, and Africa (VP, EMEA); and Laura Atallah, Head of Marketing. These leadership roles underscore HotelKey's commitment to optimizing financial performance, elevating its brand presence, and accelerating its footprint across highly competitive international hospitality markets. "We are thrilled to formally introduce these accomplished leaders who are helping drive HotelKey's operations forward," said Aditya Thyagarajan, Co-Founder & President of HotelKey. "With Julie and Laura anchoring our financial and marketing strategies, and Craig and Adnan spearheading our vital APAC and EMEA markets, we have significantly strengthened our already exceptional leadership team to execute our vision and deliver unparalleled value to our partners worldwide." Strengthening the Executive Bench Julie Arrowsmith, Executive Vice President & Chief Financial Officer (EVP & CFO) Julie oversees HotelKey's financial strategy, planning, and reporting, actively positioning the company for sustained profitability and scale. She brings over 25 years of financial expertise in the hospitality industry, including executive leadership as both CFO and CEO at G6 Hospitality, the corporate headquarters of the Motel 6 and Studio 6 brands. Prior to G6, Julie worked in public accounting with Deloitte. Working closely with the leadership team, she supports key growth initiatives, drives operational efficiency, and ensures the organization's long-term financial health, playing a pivotal role in guiding strategic decision-making. Expanding Global Reach: APAC and EMEA Craig Chait, Vice President, Asia-Pacific (VP, APAC) Driving HotelKey's rapid expansion across the Asia-Pacific region, Craig steers the company's go-to-market strategy, regional sales, and strategic partnerships. As a commercial-led B2B SaaS executive, he brings 30 years of hospitality technology experience, with prior senior leadership roles at Oracle Hospitality, Xn protel, and Planet. With a career rooted in hotel operations at Accor and Marriott, Craig leverages deep domain expertise to guide major enterprise chains through complex transitions to the cloud. Adnan Malik, Vice President, Europe, Middle East, and Africa (VP, EMEA) Adnan takes the helm of the EMEA region, where he is responsible for accelerating market penetration, building regional teams, and nurturing localized client relationships. He brings over 20 years of experience spanning London's luxury hotel segment, large-scale property operations, and enterprise SaaS. Having previously served as Managing Director of a global hospitality tech firm and CEO of an international hotel brand, Adnan offers a deep, ground-up understanding of how to align technology with enterprise growth and owner profitability. Elevating the Brand Laura Atallah, Head of Marketing Laura leads HotelKey's comprehensive marketing strategy, focusing on worldwide brand positioning, demand generation, and go-to-market initiatives. She brings over 20 years of experience in B2B SaaS and technology marketing, having previously built the marketing function for an early-stage technology company and directed high-impact campaigns at Yardi, where she led a product launch that acquired over 1,000 owner/operator clients in its first year. Known for pairing strategy with hands-on execution, Laura leverages creativity and data-driven precision to accelerate HotelKey's commercial growth. For more information about HotelKey and its leadership team, please visit https://www.hotelkeyapp.com. About HotelKey The HotelKey suite of products is a cutting-edge, cloud-based property management platform built on proven industry innovations. These advancements enable HotelKey to deliver a true plug-and-play solution that enhances revenue growth, streamlines operations, and simplifies guest interactions, empowering hotels and enterprise groups to succeed at scale. Today, HotelKey supports more than 25,000 contracted hotels, with over 15,000 live on its Hospitality Management Platform. HotelKey's customer base includes 10 enterprise hotel chains and more than 800 independent properties worldwide. Media Contact: Laura Atallah Head of Marketing, HotelKey laura.atallah@hotelkeyapp.com https://www.hotelkeyapp.com SOURCE: HotelKey

Oct 25 · 00:00ACN Newswire
Healthcare · Travel

Universal AAP: HandicapMD Highlights Medical Documentation and Attraction Access Planning

Universal access guidance connects IAC preregistration, the resort conversation, appropriate clinical support, and practical park-day arrangements. Useful preparation identifies the actual access need and the next responsible organization. Clinical documentation and a park accommodation serve different purposes.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 24, 2026 / EINPresswire.com / -- Handica

Oct 24 · 20:23EIN Presswire